The Cost of Downstream Adverse Outcomes Associated with Allogeneic Blood Transfusion: A Retrospective Observational Cohort Study.

ABSTRACT: Background: 'Downstream' adverse outcomes associated with transfusion-related immune modulation (TRIM) occur postoperatively. The potential associations between these outcomes (and costs) and perioperative transfusion are often not considered by clinicians and therefore underestimated. When considering TRIM, many advantages of intraoperative cell salvage (ICS) were previously confirmed. Methods: The main aim of this retrospective observational study was to evaluate the cost implications associated with perioperative adverse outcomes following allogeneic blood transfusion (ABT). Secondly, further analysis considered downstream costs following ICS. This manuscript does not aim to provide evidence of improved outcomes following ICS compared to ABT. These outcomes were previously

SUBMITTER: Roets M 

PROVIDER: S-EPMC11899157 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature